<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646307</url>
  </required_header>
  <id_info>
    <org_study_id>ARISE-001</org_study_id>
    <nct_id>NCT01646307</nct_id>
  </id_info>
  <brief_title>Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI</brief_title>
  <acronym>ARISE</acronym>
  <official_title>Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open label, parallel-group study is designed to investigate whether&#xD;
      periprocedural intensive statin therapy with atorvastatin versus rosuvastatin administration&#xD;
      before PCI and 30-day continuous intensive treatment is superior to usual care, in terms of&#xD;
      cardiovascular events for Chinese elderly patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1800 elderly patients (&gt;65 yr) with coronary artery disease undergoing elective PCI were&#xD;
      randomized in 2:1 fashion into either intensive statin group or standard care group. Patients&#xD;
      in intensive statin group is further randomized into two subgroups: administrated with either&#xD;
      atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days&#xD;
      after PCI; or rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d&#xD;
      for 30 days after PCI, while the standard care group receives atorvastatin 20 mg/d. After&#xD;
      angiography, patients who are not undergoing PCI procedure will be excluded from the study as&#xD;
      selection failure. The last visit will be at 6 months after PCI. Clinical data such as&#xD;
      troponin, CK-MB, Scr, CCR, ALT, AST before and 24h to 48h after procedure will be recorded.&#xD;
      1000 eligible patients will be finally enrolled.The study will be conducted at 12 centers in&#xD;
      China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day MACCEs after PCI</measure>
    <time_frame>30-day after PCI</time_frame>
    <description>30-day major adverse cardio- and cerebralvascular events (combined endpoints of cardiac death, myocardial infarction, stroke, stent thrombosis and target vessel revascularization ) after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in myocardial biomarkers (troponin I, Creatine kinase-MB)</measure>
    <time_frame>24 hours after PCI</time_frame>
    <description>changes in myocardial biomarkers (troponin I, Creatine kinase-MB)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Focus of Study</condition>
  <arm_group>
    <arm_group_label>standard care group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive atorvastatin 20 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>intensive atorvastatin</arm_group_label>
    <arm_group_label>standard care group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>intensive rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        65-80 years old Patients undergoing for elective percutaneous coronary intervention&#xD;
        Evidence of a personally signed and dated informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing emergency percutaneous coronary intervention&#xD;
&#xD;
          -  Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent&#xD;
             statin (such as simvastatin 20mg/d, pruvastatin 40mg/d, fluvastatin 80mg/d or&#xD;
             rovastatin 5mg/d ) in the next 6 months, or needing to take fibrates or niacins&#xD;
             simultaneously according to investigators' judgment.&#xD;
&#xD;
          -  LDL-C &lt; 1.8mmol/L in patients without statin therapy&#xD;
&#xD;
          -  Endstage congestive heart failure, or LVEF &lt; 30%&#xD;
&#xD;
          -  Active hepatic disease or hepatic dysfunction, or AST/ALT &gt; 1.5UNL&#xD;
&#xD;
          -  Myopathy or increased creatine kinase (CK&gt;2 UNL)&#xD;
&#xD;
          -  WBC &lt; 4×109/L or PLT &lt; 100×109/L&#xD;
&#xD;
          -  Severe renal dysfunction(Scr &gt; 3 mg/dl or 264μmol/L)&#xD;
&#xD;
          -  Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible&#xD;
             to take statin as investigator's judgment&#xD;
&#xD;
          -  Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic&#xD;
             cardiomyopathy, pericardial diseases&#xD;
&#xD;
          -  Accompanied with malignant disease or other disease, which cause life expectancy &lt; 6&#xD;
             months&#xD;
&#xD;
          -  Participating in other interventional clinical trials using drugs or devices&#xD;
&#xD;
          -  Patients with any condition which, in the investigator's judgment, might increase the&#xD;
             risk to the subject for any adverse event or abnormal laboratory finding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Jie Zhou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Gao, MD</last_name>
    <phone>86 18610323937</phone>
    <email>feigao.md@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ying-Xin Zhao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jie Zhou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>Vice President of Anzhen Hospital</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

